Back to search results

EBV Nanoparticle Vaccine Study for Healthy Adults

This study is testing two Epstein-Barr Virus (EBV) vaccines, called EBV gH/gL/gp42-ferritin and EBV gp350-ferritin, in healthy adults aged 18 to 29. EBV is a common virus that causes infectious mononucleosis (mono) and can lead to more serious illnesses. Researchers want to see if these vaccines are safe and can create a strong immune response against EBV. The study will look at any side effects you might experience after vaccination. You can join if you are healthy, whether or not you have had EBV before.

Study design
This is an interventional study with a planned enrollment of 750 participants. It is a Phase 1 study to evaluate the safety of a 3-dose vaccination regimen.
What's involved
You will have a physical examination, give blood and saliva samples, and receive three vaccine injections in your shoulder muscle over four months. You will be monitored for side effects for 7 days after each vaccination and for other issues for 30 days after each vaccination.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for unsolicited adverse events (unplanned side effects) up to 30 days after each vaccination, and for serious adverse events (SAEs) through Day 150.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06908096

Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection

Recruiting
PHASE1Ages 18–29Interventional
National Institute of Allergy and Infectious Diseases (NIAID)
~750 participants
Updated 2026-09-08 on ClinicalTrials.gov
What's tested:EBV gp350-ferritin vaccine with ALFQ adjuvantEBV gH/gL/gp42-ferritin nanoparticle vaccine with ALFQ adjuvant

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Local and systemic reactogenicity signs and symptoms during the 7-day period after each vaccination. Unsolicited AEs up to 30 days after each vaccination and SAEs through Day 150.
Measured over Through Day 150

Conditions

EBV
Epstein-Barr Virus Infection
Infectious Mononucleosis
Mono

Explore related trials

EBV Infection

NCT06908096

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • National Institutes of Health Clinical Center

    Bethesda, Marylandstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Jessica R Durkee-Shock, M.D. · PRINCIPAL_INVESTIGATOR · National Institute of Allergy and Infectious Diseases (NIAID)

Who to contact

Jessica R Durkee-Shock, M.D.
[email protected]
(301) 761-6539
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Intrauterine device (IUD) or equivalent.
Hormonal contraceptive (eg, consistent, timely, and continuous use of contraceptive pill, patch, ring, implant, or injection that has reached full efficacy prior to dosing). If the participant uses a contraceptive pill, patch, or ring, then a barrier method (eg, internal/external condom, cap, or diaphragm plus spermicide) must also be used at the time of potentially reproductive sexual activity.
A stable, long-term monogamous relationship with a partner who does not pose any potential pregnancy risk, eg, has undergone a vasectomy at least 6 months prior to the first dose of vaccine or is of the same sex as the participant.
A hysterectomy and/or a bilateral tubal ligation or bilateral oophorectomy.
External condom plus spermicide, used during sexual intercourse, even if the partner uses a contraceptive pill, patch, or ring.
A vasectomy completed at least 6 months before the first dose of vaccine.
Continuously and completely abstaining from sexual intercourse with a partner of childbearing potential from the first dose of vaccine until 30 days after the last dose.
IUD or equivalent.
Hormonal contraceptive (eg, pill, patch, ring, implant, or an injection used consistently and that has reached full effect prior to the first dose of vaccine).
Hysterectomy and/or a bilateral tubal ligation or bilateral oophorectomy.

What this trial measures

  • Local and systemic reactogenicity signs and symptoms during the 7-day period after each vaccination. Unsolicited AEs up to 30 days after each vaccination and SAEs through Day 150.Through Day 150

    To determine the safety of an adjuvanted EBV gH/gL/gp42-ferritin nanoparticle vaccine with or without gp350-ferritin nanoparticle in seronegative and seropositive healthy adults.